Navigation Links
Rheumatoid Arthritis Therapeutics in China
Date:4/9/2009

JAKARTA, Indonesia, April 9 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

In 2007, the prevalence of rheumatoid arthritis (RA) in China was 0.3 percent, and has remained stable. About three times as many women as men are afflicted with the disease. Earlier, NSAIDs were mainly used for treatment, and as the disease progressed to moderate and severe, DMARDs were introduced. However, with time, education, awareness, and treatment options, physicians have started to treat with a combination of NSAIDs and DMARDs in the early stages of treatment. Patients are also treated with traditional Chinese medicine (TCM) in combination with western medicine, or independently.

State health insurance funds the treatment cost for NSAIDs and some DMARDs such as Methotrexate (MTX). However, a majority of the population has no health insurance, putting pressure on out-of-pocket payment, or go without treatment.

Frost & Sullivan, Research Analyst Sushma Rajan says, "The diagnosis of RA is based on clinical examination of symptoms, patient history, as well as some blood tests. RA cannot be confirmed or excluded by any one test. The most common test is rheumatoid factor (RF). The other supporting tests are: anti-cyclic citrullinated peptide (Anti-CCP), erythrocyte sedimentation rate (ESR), and X-ray.

"Recent work productivity studies have confirmed that better disease awareness and availability of treatment options have resulted in fewer patients ceasing to work and more patients reporting lower impact of their disease on work as well as family and social activities," she further elaborates.

Methotrexate (MTX), a DMARD (disease-modifying anti-rheumatic drug) has been traditionally used to treat RA. It is also the most used form of treatment in rheumatoid arthritis, especially with generic forms available. Currently, combination therapies between DMARDs and NSAIDs (non-steroidal anti-inflammatory drugs) are commonly practiced.

DMARDs capture the majority of the RA therapeutics market owing to the availability of reimbursement for treatment with these drugs and their easy availability over the counter. DMARDs are expected to retain majority share in the forecast period as well.

According to Rajan, "Biologics are used in combination with DMARDs for moderate to severe RA patients. Some biologic drugs are currently reimbursed, if treated in government hospitals. Physicians opine that with more drugs brought into the hospital formularies, the usage of biologics would increase for treatment earlier in the disease."

Though there are new drugs available for treating RA, specialists in china are likely to continue using DMARDs as their first line therapy, as they have the most experience with this drug class, and it is seen as the most cost effective treatment option. Even though biologics are highly effective and recommended for treatment, they are likely to be the third line of treatment, due to their high cost. Physicians are willing to use biologics if they are listed in the hospital formulary and if they are affordable to their patients (current price range is seen to be out of reach of most patients). Physicians are of the opinion that more studies are required to make them feel confident in using biologics, but the cost of treatment is likely to restrain the high use of the drug class.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Emmie Kaur
    Corporate Communications -Healthcare, Asia Pacific
    DID: +603 6204 5913
    Email: emmie.kaur@frost.com

    Jasminder Kaur
    Corporate Communications -Healthcare, Asia Pacific
    DID: +65 6890 0937
    Email: jkaur@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genetic risk factors play role in autoantibody-negative rheumatoid arthritis
2. Patient preferences play role in racial disparities in rheumatoid arthritis treatment
3. Rheumatoid Arthritis Therapeutics in Philippines
4. Rheumatoid Arthritis Therapeutics in Thailand
5. Living Near Major Road May Boost Rheumatoid Arthritis Risk
6. Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia
7. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
8. Immune cells from patients with rheumatoid arthritis have prematurely aged chromosomes
9. Rheumatoid Arthritis Drugs Raise Shingles Risk
10. Gene Therapy May Ease Rheumatoid Arthritis
11. Process found to play role in rheumatoid arthritis could lead to new treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: